DA-11004
DA-11004 is an orally active NADP-dependent isocitrate dehydrogenase (IDPc) inhibitor with an IC50 of 1.49 μM. DA-11004 reduces NADPH production, decreases plasma NADPH levels and plasma free fatty acid levels. DA-11004 lowers plasma glucose levels, inhibits fatty acid synthesis in adipose tissue, reduces weight gain and decreases epididymal and retroperitoneal fat content. DA-11004 exerts antidiabetic effects in mice fed a high-fat and high-sugar diet. DA-11004 can be used for research on obesity and type 2 diabetes.
For research use only. We do not sell to patients.
- CAS No.: 57404-51-0
- Formula: C11H9NO2
- Molecular Weight:187.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IDPc 1.49 μM (IC50) |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, diet-induced obesity model)[1]
-
Dosage:30 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 8 weeks
-
Result:Reduced final body weight to 30.0 g, epididymal fat weight to 1.26 g, retroperitoneal fat weight to 0.65 g, plasma glucose level to 195.2 mg/dL, plasma triglyceride level to 75.1 mg/dL, plasma total cholesterol level to 99.1 mg/dL, and plasma free fatty acid level to 979 μEq/L at 30 mg/kg.
Reduced final body weight to 24.1 g, epididymal fat weight to 0.63 g, retroperitoneal fat weight to 0.30 g, plasma glucose level to 169.3 mg/dL, plasma triglyceride level to 63.2 mg/dL, plasma total cholesterol level to 105.4 mg/dL, and plasma free fatty acid level to 955 μEq/L at 100 mg/kg.
Dose-dependently inhibited plasma IDPc activity and reduced plasma NADPH levels, with the 100 mg/kg dose producing a greater effect.
Chemical Information
-
CAS No. 57404-51-0
-
Molecular Weight 187.20
-
Formula C11H9NO2
-
SMILES
O=C1C=C(NC)C=2C=CC=CC2C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Large-size fat particle sorting
Large-size fat particle sorting is widely used to isolate cells up to 200 μm in diameter. Single-cell flow sorting will allow greater insight into adipocyte heterogeneity by identifying gene expression, protein composition, and metabolic signatures at the single-cell level.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)